The guidance provides recommendations
to industry on formal meetings between FDA and sponsors or
applicants relating to the development and review of biosimilar
biological products regulated by the Center for Drug Evaluation and
Research (CDER) and the Center for Biologics Evaluation and
Research (CBER). The guidance assists sponsors and applicants in
generating and submitting meeting requests and the associated
meeting packages to FDA for biosimilar biological
products.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.